[go: up one dir, main page]

WO1998004293A1 - Amelioration de la detection et du traitement de lesions par des conjugues chelates de la biotine - Google Patents

Amelioration de la detection et du traitement de lesions par des conjugues chelates de la biotine Download PDF

Info

Publication number
WO1998004293A1
WO1998004293A1 PCT/US1997/013285 US9713285W WO9804293A1 WO 1998004293 A1 WO1998004293 A1 WO 1998004293A1 US 9713285 W US9713285 W US 9713285W WO 9804293 A1 WO9804293 A1 WO 9804293A1
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
biotin
detection
chelate
tissue
Prior art date
Application number
PCT/US1997/013285
Other languages
English (en)
Inventor
Gary L. Griffiths
Hans J. Hansen
Habibe Karacay
Original Assignee
Immunomedics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics, Inc. filed Critical Immunomedics, Inc.
Priority to AU40474/97A priority Critical patent/AU4047497A/en
Publication of WO1998004293A1 publication Critical patent/WO1998004293A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention relates to methods for detecting and treating pathological conditions with a multi-step process using improved detection or therapeutic chelate conjugates comprised of biotin, chelator, and optional linker.
  • the targeting antibody is conjugated to an appropriate detection or therapeutic agent as described, for example, in Hansen et al . , U.S. patent No. 3,927,193 and Goldenberg, U.S. patent Nos. 4,331,647, 4,348,376, 4,361,544, 4,468,457,
  • Radioimmunotherapy An important therapeutic method that uses antibody targeting is radioimmunotherapy. It cannot be overstressed that the fundamental limitation to radioimmunotherapy is the low absolute amount of therapy nuclide that can be delivered to a target . Poor targeting of a nuclide, determined as a poor target :back- ground ratio, contributes to the problem by restricting the amount of delivered nuclide still further, according to the ability of non-targeted tissue to withstand deleterious effects of the nuclide present there due to background binding .
  • An important technical development which increases the target : background ratios when using detection or therapeutic agents is the "pre-targeting" approach, as described, for example, in Goodwin et al . , U.S. Patent No.
  • the pre-targeting approach decouples the therapy agent delivery step from the antibody targeting step.
  • An example of pre-targeting in the context of tumor radiotherapy is the administration of a conjugate comprising a tumor specific antibody and a second binder to a cancer patient.
  • the conjugate circulates within the patient's body and some of the conjugate binds to the tumor by affinity between the antibody moiety and a tumor-specific antigen on tumor cells.
  • Conjugate that does not adhere to the tumor clears gradually over time, preferably by administration of a specific clearing agent .
  • a therapeutic agent -chelate conjugate that binds to the second binder moiety of the conjugate is administered.
  • the therapeutic agent -chelate conjugate localizes to tumor by virtue of its affinity to the second binder in the antibody- conjugate that has been pre-targeted to tumor.
  • the pre-targeting approach uses two binding partners, such as avidin and biotin, to indirectly localize a detection or therapeutic agent to target tissue. For example, in a "2-step" procedure, a targeting antibody- avidin conjugate, having an avidin as "second binder", first is injected into a patient and the antibody-avidin localizes to a target tissue.
  • biotin conjugated to a detection or therapeutic agent is injected and binds to the avidin pre-localized to the target tissue. Timing of the second injection after the first one is critical. Injecting a biotin chelate conjugate too early will increase the proportion of biotin chelate conjugate that remains in the bloodstream. On the other hand, injecting the biotin chelate conjugate very late may decrease the amount of biotin that localizes to a tumor because of reduced retention of the targeting protein at the tumor with time. This results in decreased accretion of the therapeutic agent, which is part of the chelate conjugate, at the tumor
  • a "3 -step" procedure also has been developed to improve target to background ratios of antibody-avidm (or biotm) conjugate that becomes localized to target tissue.
  • administration of a targeting antibody-avidin (or biotm) conjugate is followed by administration of a clearing agent to remove unbound conjugate.
  • a biotmylated polymer such as biotmylated human serum albumin. This type of agent forms a high molecular weight species with circulating antibody-avidm conjugate.
  • nuclide therapy as outlined above is limited by the accretion of therapeutic nuclide to the tumor site.
  • carrier molecules that lack a functioning detection or therapeutic agent typically are in great excess over functional carrier molecules.
  • much less than one percent of targeted antibodies usually receive an atom of isotope If all, or virtually all targeted antibodies could receive one or more atoms of a therapeutic isotope, the effectiveness of these methods could be improved greatly.
  • nuclide chelator conjugates used have very low specific activities.
  • the low specific activity of these conjugates often is a consequence of difficulties in purifying a protein-nuclide chelate conjugate away from protein that does not have a radionuclide complexed to it.
  • Another cause of the low accretion problem is that the body residence time of a diagnostic or therapeutic agent, expressed as its half-life, i.e. how long half of a parenterally injected dose stays inside the body, is uncontrolled.
  • An excessively long body residence time will unnecessarily expose untargeted body tissues to the detection or therapeutic agent and cause side effects. These side effects limit how much radionuclide can be used.
  • the body residence time is too short, then the injected agent will not have enough time to saturate and bind all pre-targeted antibody- conjugate. Consequently, less detection or therapeutic agent is delivered to the target .
  • a small detection or therapeutic agent having a molecular weight less than about 40,000 daltons can be quickly removed by kidney filtration.
  • the ideal detection or therapeutic chelate conjugate for use in these methods has a small size and is quickly cleared by the kidney, yet has a body residence time sufficient for it to saturate target sites.
  • the ideal body residence time is determined by a number of factors, including the nature of the target, targeting conjugate, kidney health, half-life of detection or therapeutic agent, and binding moieties used to bind the detection or therapeutic agent to the targeted site.
  • known methods do not provide convenient control of body residence time for delivery of detection or therapeutic agent .
  • a means to control body residence time would give significant clinical benefits, particularly with pre- targeting strategies that are sensitive to the timing of injections .
  • Kidney resorption capacity can be altered by chemical agents for controlling body residence time of therapeutic proteinaceous agents. For example, US patent No.
  • 5,380,513 discloses the use of cationic compounds such as lysine, that promote urinary excretion of protein.
  • cationic compounds such as lysine
  • basic amino acids have been used to block kidney resorption of low molecular weight peptides as well as protein, the effects of these chemical agents are generalized and not limited to specific medicinal reagents. Fewer side effects would result if kidney resorption capacity only could be modified for a particular medicinal reagent.
  • the new pretargeting methods solve the target : background ratio problem but do not alleviate the fundamental problem of low accretion.
  • multi-step procedures can specifically locate antibody or other binding protein onto target surfaces, in reality, few of the located proteins receive a detection or therapeutic agent. If all, or substantially all pre-targeted protein could receive at least one detection or therapeutic agent, then clinical effectiveness could be greatly improved.
  • a further objective of the present invention is to provide a detection or therapeutic agent with an increased specific activity, and to allow delivery of higher amounts of detection or therapeutic agents to a targeted cell, tissue, or pathogen.
  • a method for detecting or treating a target cell, tissue or pathogen in a patient comprising pre-targeting the target cell, tissue, or pathogen with avidin, using a targeting protein that specifically binds a marker substance on the target cell, tissue, or pathogen and to which avidin is bound either directly as an avidin-targeting protein conjugate, or indirectly via non-covalent binding of avidin to a biotin-targeting protein conjugate; parenterally injecting a detection or therapeutic composition comprising a chelate conjugate of biotin, a chelator, and a chelatable detection or therapeutic agent, and allowing the composition to accrete at the targeted cell, tissue, or pathogen; wherein the chelate conjugate is purified by chromatography after chelate formation, or further comprises a blood transit -modifying linker or addend that is covalently bound within the chelate conjugate, or both; and using the detection or therapeutic agent to detect or treat the targeted cell, tissue,
  • Objectives of the invention also are achieved by providing a method for detecting or treating a target cell, tissue or pathogen in a patient, the method comprising pre-targeting the target cell, tissue, or pathogen with avidin, using a targeting protein that specifically binds a marker substance on the target cell, tissue, or pathogen and to which avidin is bound either directly as an avidin-targeting protein conjugate, or indirectly via non-covalent binding of avidin to a biotin-targeting protein conjugate; parenterally injecting a detection or therapeutic composition comprising a biotin- ultiple chelate conjugate and a chelatable metal ion detection or therapeutic agent, and allowing the composition to accrete at the targeted cell, tissue, or pathogen; wherein the biotin-multiple chelate conjugate comprises at least five chelates, and using the detection or therapeutic agent to detect or treat the targeted cell, tissue, or pathogen.
  • a sterile injectable composition for human use comprising a detection or therapeutic composition comprised of a chelate conjugate of biotin, chelating agent, and chelatable therapeutic or detection agent; or biotin, chelating agent, blood transit modifying linker or addend, and chelatable therapeutic or detection agent.
  • RAIT radioimmunotherapy
  • therapeutic agent such as a nuclide accrete to target sites in a patient.
  • This limitation is compounded by the target-to-tissue ratio in standard RAIT protocols.
  • radionuclide toxicity limits how much circulating radionuclide attached to antibody can be delivered to a target.
  • a large amount of radionuclide is introduced into a patient, a large proportion of the introduced nuclide binds to target and excess nuclide quickly is removed from the body.
  • Decoupling the antibody and nuclide delivery steps by using a pretargeting method improves the proportion of nuclide that binds specifically to target tissue but does not address the related problem of low absolute target accretion. Furthermore, even in the newer methods, fewer than ten percent of target antibodies typically receive a desired nuclide in the context of radiotherapy. Consequently, these methods could be improved greatly if a means were found to bind at least one functional detection or therapeutic agent to each pre-targeted protein.
  • the inventors discovered several means to achieve this, including purification of radionuclide after chelate formation and placing multiple chelates in one conjugate.
  • the amount of radionuclide accreting at a target can be increased by optimizing the body residence time of the conjugate.
  • the invention provides typically a 100 to 1000 fold increase in the delivery of isotope to a tumor by combining one or more of these techniques with selection of a suitable isotope and of a good first step agent such as strepavidin-antibody to localize the isotope.
  • the increase in total amount of delivered radionuclide made possible by the invention, together with a dramatic increase in "therapeutic ratio" provided by the pretargeting approach allows successful transfer of radioimmunotherapy from animal subjects to human subjects .
  • the invention contemplates increasing the absolute amount of radiolabelled biotin (or avidin) that accretes to targets by alternate means of (1) purifying isotope after chelate formation, (2) linking multiple radiolabels onto one binding site via a polymeric chelate substituted with a single biotin (or avidin) , termed "multiple chelate conjugate” and (3) saturating pre-targeted antibody-avidin binding sites by controlling the blood clearance of biotin-chelate- nuclide .
  • Radionuclide-chelator-biotin conjugate is a preferred means to solve the low specific activity problem. Due to a nuclide 's cationic nature, the small size of biotin, and the small size of most chelators, a chelate-biotin conjugate that contains the nuclide can be conveniently purified away from a conjugate that lacks the desired nuclide. Consequently, a therapeutic agent composition of much higher specific activity can be delivered to a target.
  • the detection or therapeutic chelate conjugate preferably is purified immediately prior to use.
  • purification to increase its specific activity can be performed prior to storage .
  • the polymer backbone size can be selected from a wide variety of sizes such as from 200 daltons in molecular weight up to 2,000,000 daltons in molecular weight and can be a polyamino acid, polysugar, polyacid, polyamine, or polyalcohol .
  • the polymer comprises at least two chelates. Preferably the polymer comprises at least 5 chelates and more preferably at least 25 chelates.
  • the polymer may be selected according to the pharmacokinetic properties that it brings to the final radiolabeled biotin conjugate.
  • the molecule When using a naturally occurring molecule to form the multiple chelate conjugate, the molecule is large enough to contain at least 2 natural chelating sites, preferably at least 3 natural sites, and more preferably at least 5 sites.
  • Most preferred in this context is metallothionein.
  • Biotin can be attached to an amino group of metallothionein and radiometals that bind strongly to sulfur atoms are attached to the apometallothionein-biotin conjugate.
  • Such a metallothionein agent can bind up to seven atoms of elements such as copper, zinc, rhenium and similar thiophilic metals.
  • Metallothionein is preferred because it is non-immunogenic and, as a thioprotein, will not bind well to all metals.
  • a desired consequence of metallothionein 1 s metal specificity is that iron contamination of metallothionein radionuclide conjugates such as those made from radiorhenium is much less than that of prior art chelators such as EDTA-type agents.
  • Accretion of radionuclide to a target site can be increased by modifying a chelate conjugate to alter its renal clearance rate and thus its body residence time.
  • a "linker" moiety to link biotin with chelator can be designed or chosen having a predictable kidney clearance ratio.
  • the present inventors discovered that renal clearance of a chelate conjugate that comprises a detection agent could be adjusted by designing a linker having a particular composition because the linker can dominate the overall blood clearance characteristics of the chelate conjugate.
  • the selection of a linker is determined by analyzing the ionic, hydrophobic, and steric characteristics needed to match kidney physiology and to delay or facilitate the excretion of the detection or therapeutic agent by the kidney.
  • a particular linker also may be chosen on the basis of resistance to proteases and to biotinidase.
  • the excretion of a substance that is filtered, but not reabsorbed or secreted by the kidney is controlled by the sieving properties of the kidney glomerular wall. How well the kidney excretes such a substance can be determined by measurements of the clearance of a test molecule, relative to some "freely permeable" reference polymer such as inulin, as summarized by Brenner et al . in Am . J. Physiol . 234: F455-60 (1978), which is herein incorporated in its entirety by reference.
  • the ratio of urinary clearance of a test solute to a reference solute is equal to the ratio of the concentration of the test solute in Bowman's space to its concentration in plasma water. This ratio is called the "fractional clearance" of the test solute.
  • the fractional clearance varies from 0, when test molecules cannot enter the kidney filtrate, to 1 when they encounter no measurable restriction to filtration.
  • a chelate conjugate that has a fractional clearance near 1 is quickly cleared by the kidney (if not reabsorbed by the kidney) and has a short body residence time, l e. fast renal clearance.
  • a chelate conjugate that has a fractional clearance near zero typically is cleared slowly by the liver or other tissue, and has a longer body residence time, i.e slow renal clearance
  • a "chelator”, as used in the present invention, is a polyfunctional compound having a chelating group and at least one pendant functional group
  • the chelating group can chelate a radionuclide.
  • the pendant functional group may be the same as or different from the chelating group, and can covalently bind to a linker or to biotin
  • Chelating agents may be represented by the formula A(F) n wherein A represents the chelating moiety, F represents a pendant functional group, and n is an integer from 1 to 3 , preferably 1.
  • Groups that are capable of chelating radionuclides include macrocycles, linear ligands, or branched ligands.
  • macrocyclic chelating moieties include polyaza- and polyoxamacrocycles , and poly (thioalkyl) azamacrocycles .
  • polyazamacrocyclic moieties include those derived from compounds such as the preferred 1,4,7,10- tetraazacyclododecane-N,N' ,N' ' ,N" ' ' -tetraacetic acid (herein abbreviated as DOTA) ; 1,4,7,10- tetraazacyclot ⁇ decane-N, N' ,N' ' ,N' ' ' -tetraacetic acid, 1,4,8, ll-tetraazacyclotetradecane-N,N' , N' ' ,N' ' ' - tetraacetic acid; and 1, 5 , 9 , 13-tetraazacyclohexadecane- N,N' ,N' ' ,N' ' • -tetraacetic acid.
  • DOTA 1,4,7,10- tetraazacyclot ⁇ decane-N, N' ,N' ' ,
  • linear or branched chelating moieties include those derived from compounds such as ethylenediaminetetraacetic acid (herein abbreviated as EDTA) and diethylenetriamine- pentaacetic acid (herein abbreviated as DTPA) .
  • EDTA ethylenediaminetetraacetic acid
  • DTPA diethylenetriamine- pentaacetic acid
  • Chelating moieties having carboxylic acid groups may be derivatized to convert one or more carboxylic acid groups to amide groups.
  • Synthetic methods for the preparation of chelating agents useful in the practice of the invention are known. See for example, Cox et al . , J. Chem . Soc . , Perkin Trans . 1: 2567-76 (1990) and Moi et al . , J. Am. Chem . Soc . 110: 6266-7 (1988).
  • the present invention also contemplates chelators that bind soft acid metal cations.
  • Such chelators include polypeptides such as metallothionein and metallothionein fragments, porphyrins, amine- terminating bifunctional chelating reagents and other molecules that use nitrogen and/or thiol ligands (e.g. N 2 S 2 ; N 3 S ligands) to bind soft acid metal cations such as rhenium-188, cadmium, silver, mercury, copper, and zinc.
  • a "soft acid metal cation" is one which preferentially binds with a nitrogen or sulfur containing ligand, especially a thiol, rather than an oxygen containing ligand.
  • short peptides can be made and are contemplated for use in this invention. In fact, virtually all combinations of amino acids that are shorter than 400 amino acid residues long could be employed for some purposes as a linker. Preferred are short polypeptides of less than about 50 amino acid residues, and most preferably less than ten residues. Especially preferred are peptides that contain a basic amino acid such as lysine, which, for some nuclides, can balance out a negatively charged chelate.
  • a basic amino acid such as lysine
  • D-amino acids are preferred for chelate conjugates having good serum stability. Peptide bonds formed from the D-amino acids are much less susceptible to proteolysis, and chelate conjugates made from D-amino acids are longer lived in the circulation (i.e. have longer "body residence” times) . Also, chelate conjugates formed from D-amino acids are more resistant to biotinidase activity.
  • biotin-polypeptide-chelator chelate conjugates include:
  • a peptide can be used as a combined chelator and linker.
  • metallothioneins and peptide fragments of metallothioneins such as the metallothionein C- terminal fragment KCTCCA, and glutathione derivatives.
  • Metallothioneins are described in Metallothioneins : Proceedings of the First International Meeting on Metallothionein and Other Low Molecular Weight Metal - Binding Proteins, Zurich, July 17-22, 1978, p. 46-92, ed. by Kagi and Norberg, Birkhause Verlag Basel, (1979) which is incorporated herein by reference.
  • Metallothionein fragments are preferred in the practice of this invention as are functionally similar polypeptides having at least about six amino acid residues .
  • Metallothioneins can chelate a wide variety of metal ions with high affinity. Because the sulfhydryl moieties in these molecules are bound to metal ions, they are generally not available to serve as functional groups for direct conjugation to biotin or indirect conjugation through a linker, but other groups, such as -NH 2 , -OH and -C00H groups are available for this purpose .
  • Metallothioneins, metallothionein fragments, and glutathione derivatives can be covalently conjugated to targeting proteins using reagents and methods which utilize these groups, while essentially not interfering in the polypeptide ' s metal -binding capability.
  • a ine-terminating bifunctional chelating reagents contain pendant thiol and amine groups which are suitably disposed to tightly bind radioactive metals such as 186 Re, 18 Re, m Ag, and 67 Cu .
  • Conjugation of a BFC to a carbohydrate linker is achieved through an amine or hydrazine function on the BFC, which can respectively form an imine Schiff base) or hydrazone linkage to an aldehyde or ketone function on the carbohydrate after its oxidation.
  • Imine linkages can be stabilized by reduction with a reducing agent such as sodium cyanoborohydride .
  • the thiol group of the chelator moiety is masked as a thiol ester or disulfide, and is deprotected after the preparation of the chelate conjugate.
  • the BFCs can be described by the general structures la, lb, and Ic:
  • X is CH, or X and Z taken together can be CO;
  • Y is CR 4 R 5 , CH 2 CR 4 R 5 or (CH 2 ) 2 CR 4 R 5 where R 4 and R 5 are the same or different and are selected from the group consisting of hydrogen, C, to C 2 ⁇ straight chain, branched or cyclic alkyl, optionally substituted with hydroxy, alkyloxy, nitro, halogen and the like, C 4 to C 20 homoaryl or heteroarylaryl , heteroaryl being one or more aromatic rings containing one or two oxygen, nitrogen or sulfur atoms, the aryl group being optionally substituted with hydroxy, alkyloxy, nitro, halogen and the like;
  • Z can be any group capable of reacting with an oxidized carbohydrate, or Z can be H;
  • R 1 is a thiol protecting group;
  • R 2 and R 3 can be the same or different, and each is selected from the group consisting of hydrogen, C, to C 2() straight chain,
  • D is H or CH 2 SR' ;
  • E can be any group capable of reacting and/or complexing with the linker;
  • R 1 is a thiol protecting group, and
  • m is 0, l, 2, or 3.
  • Q can be any group capable of reacting and/or complexing with the linker;
  • R 1 is a thiol protecting group; and each n independently is 2 or 3.
  • Representative examples of la, lb, and Ic are provided in the Examples below. In some of these examples, the linker-binding group is shown as, but not limited to, a hydrazide.
  • the thiol protecting group used in the BFC can be any organic or inorganic group which is readily removed to regenerate the free sulfhydryl in the presence of linker.
  • suitable protecting groups include thiol esters, thiocarbamates and disulfides.
  • the thiol protecting group is a benzoate thioester.
  • benzoate thioesters may be deprotected under mild and selective conditions using hydroxylamine .
  • Biotin as a binding partner, can be, inter alia , modified by the addition of one or more addends, usually through its free carboxyl residue.
  • Useful biotin derivatives include active esters, amines, hydrazides and thiol groups that are coupled with a complimentary reactive group such as an amine, an acyl or alkyl group, a carbonyl group, an alkyl halide or a Michael-type acceptor on the appended compound or polymer.
  • NHS-LC-biotin are commercially available and can be attached to a bifunctional chelator such as ITC-Bz-DTPA.
  • Shih et al . in U.S. patent No. 5,057,313, hereby incorporated in its entirety by reference, describes reactions for forming conjugates between amino and carboxy functionalized molecules, and between amino or hydrazide groups and aldehyde or ketone carbonyls resulting from oxidative cleavage of carbohydrates. These reactions are suitable for conjugating biotin with a linker and for conjugating biotin directly with a chelator.
  • D-amino acids and D-amino acid peptides can form more stable linkages between biotin and chelators and are preferred alternatives.
  • One or more D-amino acids can be used to link biotin and a chelator.
  • the peptide ' s hydrophobicity can be adjusted for example, by increasing the number of phenylalanines or other hydrophobic residues within the linker to achieve a desired body residence time.
  • the number of chelators per biotin can be increased by coupling more chelators, through multiple amino acid residues, in the linker.
  • the primary amino acid residues of lysine are a preferred embodiment in this context. By attaching one chelator per lysine residue, and incorporating multiple lysine residues in the biotin-peptide the specific activity of the chelate conjugate can be increased.
  • a biotinylated peptide can be synthesized easily by a manual solid phase technique or by an automated peptide synthesizer.
  • avidin includes all of its biological forms either in their natural states or in their modified forms. Avidin, found in egg whites, has a very high binding affinity for biotin, which is a B- complex vitamin (Wilcheck et al., Anal. Bioche , 171:1, 1988) . Streptavidin, derived from Streptomyces avidinii , is similar to avidin, but has lower nonspecific tissue binding, and therefore often is used in place of avidin. Modified forms of avidin which have been treated to remove the protein's carbohydrate residues ( "deglycosylated avidin"), and/or its highly basic charge (“neutral avidin”), for example, also are useful in the invention.
  • Both avidin and streptavidin have a tetravalency for biotin, thus permitting amplification when the former bind to biotin.
  • Four detection or therapeutic agents, such as nuclides, can be attached to each targeting protein by the methods of the present invention.
  • gamma-emitters, positron-emitters, x-ray emitters and fluorescence- emitters are suitable for localization and/or therapy, while beta and alpha-emitters and electron and neutron- capturing agents, such as boron and uranium, also can be used for therapy.
  • beta and alpha-emitters and electron and neutron- capturing agents such as boron and uranium
  • cytotoxic drugs that can become chelated are known to those skilled in the art and are useful for the present invention. Suitable compounds can be found in compendia of drugs and toxins, such as the Merck Index, Goodman and Gilman, and the like, and in the references cited above.
  • Useful diagnostic radionuclides include Ruthenium- 95, Ruthenium-97, Ruthenium- 103 , Ruthenium-105 , Technetium-99m, Mercury-197, Gallium-67, Gallium-68, Osmium-191, Indium-Ill, Indium-113 and Lead-203.
  • Useful therapeutic radionuclides include Antimony- 119, Act ⁇ mum-225, Rhemum-186, Rhen ⁇ um-188, Rhen ⁇ um-189, S ⁇ lver-111, Platmum-197, Pallad ⁇ um-103 , Palladium- 109, Copper-67, Yttr ⁇ um-90, Scand ⁇ um-47, Samar ⁇ um-153 , Lutet ⁇ um-177, Rhod ⁇ um-105, Praseodym ⁇ um-142 ,
  • Praseodymium- 14 Terb ⁇ um-161, Holm ⁇ um-166, Lead-212, B ⁇ smuth-212, Gold-198 and Gold-199.
  • a chelate is formed between the chelator and a chelatable detection or therapeutic agent such as a nuclide, using methods known in the art.
  • a chelatable detection or therapeutic agent such as a nuclide
  • the chelator is dissolved in a buffered aqueous medium and a purified radionuclide is added
  • the pH may be selected to optimize chelate formation.
  • the pH may be adjusted (using, for example, aqueous tetramethylammonium acetate) , to obtain a pH of about 3 to about 6, and more preferably about 5 to provide a preponderance of ionized carboxylate (-C00-) groups, and thereby yield a chelating species which is anionic.
  • the reaction mixture temperature may be adjusted, for example to 37°C for 30 minutes, to accelerate the chelation reaction After a period of time or upon completion of the reaction, an excess of an appropriate quenching agent, such as DTPA
  • the quenching agent acts to form anionic chelates with any radionuclide not yet chelated by the chelating agent.
  • the resulting reaction mixture may then be purified to a high specific activity.
  • the chelate should have the highest specific activity possible. Purification is preferably carried out by chromatography and more preferably by ion exchange chromatography. A number of chromatographic techniques are known n the art and can be used. Methods for purifying chelate prior to conjugation with protein are known, as typified by Li et al . , Bioconj uga te Chem . 5: 101-4 (1994), which is herein incorporated in its entirety by reference. The preferred type of chromatographic material is determined by the properties of the chelator.
  • the chelator When the chelator has a net charge near zero it becomes a cation upon chelate formation with a metallic nuclide and preferably is purified by cation exchange chromatography, and most preferably with DEAE cellulose prepared in an acetate form.
  • a DOTA-peptide -biotin chelator conjugate having a net charge of (-3) at physiological pH is used to chelate a metal (+3) cation and form a neutral chelate conjugate.
  • the metal - containing chelate conjugate is purified from non- metal -containing chelator by anion exchange chromatography .
  • a skilled artisan can estimate what size of polymer and what kinds of charges are most suitable for the linker, based on the predicted size, i.e. the effective molecular radius, of the completed chelate conjugate. Alternately, fractional clearances can be determined by experimentation.
  • Uncharged polymers such as dextran have a fractional clearance of 1 when they have an effective molecular radius of about 18 angstroms or less. Such polymers have a fractional clearance of about 0 when they have an effective molecular radius of about 44 angstroms or more.
  • a non-charged polymer such as polyethylene glycol or dextran which is not reabsorbed by the kidney can be a linker.
  • the biotin-linker-chelator-nuclide conjugate should have an effective molecular radius of more than 18 angstroms in order to prolong its body residence time, compared to a small molecule that is filtered without restriction by the kidney.
  • the chelate conjugate should, at the same time, have an effective molecular radius of less than about 44 angstroms in order that the kidney gradually clear it from blood. If the effective molecular radius is significantly more than 44 angstroms then the body residence time will be too long and a mechanism different from kidney clearance may dispose of the chelate conjugate.
  • the selected linker can have one or more negative charges. If a polyanionic linker, such as, for example, dextran sulfate is used, then the chelate conjugate size should be smaller to obtain the same degree of fractional clearance by the kidney. For example, a dextran polymer- based chelate conjugate having an effective molecular radius of 18 angstroms will have a fractional clearance of about 1 (quickly removed by passing through the kidney) , but a dextran sulfate-based chelate conjugate having an effective molecular radius of 18 angstroms will have a fractional clearance closer to 0.5, and will be removed from the blood more slowly.
  • the selected linker can have one or more positive charges.
  • a positively charged linker such as a short polypeptide having lysine and/or arginine residues will effect more rapid kidney clearance of the chelate conjugate .
  • the size and charge of the complete conjugate made from biotin, linker, chelator, and chelated detection or therapeutic agent is considered when estimating fractional clearance.
  • the linker may dominate the chelate conjugate's blood residence time.
  • the linker should be chosen such that the chelate conjugate's effective molecular radius is between about 18 and about 42 angstroms.
  • the effective molecular radius should be smaller, depending on how many excess negative charges are in the chelate conjugate.
  • the effective molecular radius should be between about 15 and about 32 angstroms.
  • the linker should be chosen to give a slightly greater effective molecular radius of the chelate conjugate in comparison to that for neutrally charged chelate conjugates.
  • Blood residence time also can be controlled by altering the linker's hydrophobicity .
  • Polypeptides are preferred for this use.
  • One or more hydrophobic amino acid residues such as phenylalanine, tryptophan, tyrosine, leucine, isoleucine, or valine in the peptide linker will increase the hydrophobicity of the chelate conjugate.
  • Adding one or more hydrophobic residues to the chelate conjugate can both alter the effective molecular radius of the chelate conjugate and increase the chances that the chelate conjugate will interact with other proteins in the blood.
  • hydrophobic residue a mechanism for prolonging the blood residence time of small chelate conjugates that contain hydrophobic residue (s) is the ability of the chelate conjugate to associate with serum albumin and escape filtration by the kidney.
  • a chelate conjugate having one or more hydrophobic residues such as for example, a long aliphatic chain, a phenyl ring, an imidazole, and the like, may have affinity for the hydrophobic binding site of serum albumin.
  • Alternative chelate conjugates can be tested for their relative blood residence times by comparing how well they associate with serum albumin.
  • a carrier that has hydrophobic residue (s) is particularly suited for the formation of a detection or therapeutic chelate conjugate that provides a detection or delivery agent over a longer time period.
  • the optimum body residence time for a given set of conditions can be determined experimentally.
  • a very short half-life nuclide works best in combination with chelate conjugates that are cleared more rapidly by the kidney.
  • a chelate conjugate that exhibits a small effective molecular radius and which is not very hydrophobic will exhibit a short body residence time.
  • Linkers that cause a fractional clearance of near 0 or that cause the chelate conjugate to bind to serum protein are more preferred for long half -life isotopes. This kind of reagent would behave like a time-release capsule and slowly localize at the target site.
  • hydrophobic linker can prolong the serum half life of the detection or therapeutic chelate conjugate. Consequently, an isotope of shorter tissue range (lower decay energy) and longer half -life can be employed to spare blood and marrow cells while delivering a sustained dose- level to a target.
  • the methodology used in this approach in essence, allows the choice of possible radiotherapeutic isotopes to be expanded considerably .
  • a physiological solution of the biotin-chelator conjugate is advantageously metered into sterile vials, e.g., at a unit dosage of about 0.1 - 500 mg of the chelator conjugate, and the vials are either stoppered, sealed and stored at low temperature, or lyophilized, stoppered, sealed and stored.
  • the vial contents can be reconstituted with a solution containing the metal ion to be chelated.
  • the detection or therapeutic biotin- chelate conjugate is injected parenterally after a pre- targeted antibody conjugate has had time to localize to a targeted cell, tissue or pathogen.
  • the biotin-chelate detection or therapeutic conjugate is injected after the clearing and localizing agent in a 3 - step method.
  • Parenteral administration comprises intravenous, in t r aar t e r i al , int r ap 1 eural , intraperitoneal, intrathecal, subcutaneous and perfusion administration.
  • the improved method of the present invention can enhance detection (either by internal procedures or by external imaging) and/or enhance treatment of lesions, including cancers, infectious diseases, cardiovascular diseases and other pathological conditions as part of a pre-targeting procedure.
  • pre-targeting procedures utilize targeting protein to locate a biotin detection or therapeutic agent to a target site.
  • the targeting protein comprises a protein, peptide, polypeptide, glycoprotein, lipoprotein, or the like, e.g. hormone, ly phokine, growth factor, albumin, cytokine , enzyme, immune modulator, receptor protein, antibody and antibody fragment .
  • Internal detection procedures in the context of the invention comprise intraoperative, intravascular or endoscopic, including laparoscopic, techniques, both surgically invasive and non-invasive. Examples of appropriate applications are provided in the above- referenced and incorporated Goldenberg patents and applications .
  • the cancer states include carcinomas, melanomas, sarcomas, neuroblastomas, leuke ias, lymphomas, gliomas and myelomas.
  • the infectious diseases include those caused by invading microbes or parasites.
  • microbe denotes virus, bacteria, rickettsia, mycoplasma, protozoa, fungi and like microorganisms
  • parasite denotes infectious, generally microscopic or very small multicellular invertebrates, or ova or juvenile forms thereof, which are susceptible to antibody- induced clearance or lytic or phagocytic destruction, e.g., malarial parasites, spirochetes and the like, including helminths
  • infectious agent or "pathogen” denotes both microbes and parasites.
  • the improved pre-targeting methods of the invention increase the sensitivity of the above recited detection procedures and increases the efficacy of the above recited therapeutic procedures.
  • these embodiments constitute improved methods and reagents for detection and therapy of cancer and other pathological conditions.
  • a polypeptide having at least one free amino group at a concentration of 10 mg/ml in a borate buffer, 0.1M, pH 8.5 is mixed with a 10 fold molar excess of an activated sulfosuccini ide ester of D-biotin.
  • the reaction solution is stirred for 16 hours and kept at a temperature of 25°C.
  • the modified polypeptide is separated from unbound biotin and other low molecular weight contaminants by size- exclusion or ion exchange chromatography.
  • a DMSO co-solvent is added up to a 20% concentration to facilitate reactant solubility.
  • the reaction solution is stirred for 1 hour at a temperature of about 25°C.
  • the biotinylated polypeptide is separated from unbound biotin and other low molecular weight contaminants chro atographically.
  • Dextran at a concentration of 1 mg/ml is treated with sodium metaperiodate to a final concentration of 0.03 mg/ml in phosphate buffered saline at room temperature for 4 hours.
  • the oxidized dextran is purified from sodium metaperiodate by size -exclusion chromatography in phosphate buffer, 0.1 M, pH 7.5.
  • the oxidized dextran (1 mg/ml) is reacted with biotin-hydrazide (Pierce Chemical Co.) in 0.1 M phosphate buffer, pH 7.5 for 6 hours at 37°C. After coupling, the formed hydrazone is reduced by the addition of sodium cyanoborohydride with stirring overnight.
  • the biotinylated dextran is purified by size- exclusion chromatography on a G-25 Sephadex column.
  • N-hydroxysuccinimide ester of DOTA (1,4,7,10- tetraazacyclododecane N, N , N , N " -tetraacetic acid) is prepared by modification of a procedure described by Lewis et al . , Bioconjugate Chem. 5: 565-76 (1994) .
  • a solution of biotinyl-peptide-DOTA is treated with a 0.01-1 mol solution of gadolinium cation in acetate buffer at a pH of 5 for 3 hours at 37°C.
  • the metallated biotin-peptide-DOTA is separated from unincorporated metal chromatographically .
  • Example 4 Construction of Chelate conjugates that contain a D-amino acid
  • the peptides, 1) biotin- (D) -Lys-NH 2 , 2) biotin- (D) - Phe- (D) -Lys-NH 2 and 3) biotin- (D) -Phe- (D) -Phe- (D) -Lys-NH 2 were synthesized manually by standard Fmoc procedures on a Rink resin (Advanced ChemTech; 0.56 mmol/g) according to published procedures.
  • Fmoc amino acids (advanced ChemTech) were assembled on Rink resin using HOBT and a DIC coupling procedure.
  • (+) -biotin was coupled using HBTU, HOBT and DIPEA 0.15 M in DNC except for DIPEA (0.75 M) .
  • a minimum amount of N-methyl pyrrolidone was added to aid in solubilization .
  • the peptides were cleaved from the resin with a solution of 91 % TFA, 4.5 % H 2 0 and 4.5 % ethylmethyl sulfide.
  • the crude peptides were treated with 0.3- 0.5x molar excess of ITC-Bz-DTPA in H 2 0 at pH 8.6 at 37" C until all of the ITC-Bz-DTPA was consumed as monitored on an analytical HPLC column.
  • the peptide bio- (D) -Phe- (D) - Phe- (D) -Lys-NH 2 required acetonitrile for solubilization in H 2 0.
  • Biotinylated peptide complexes and the unreacted peptides were isolated following purification on a preparative C-18 HPLC column using the gradient 0-70 % B in 40 min at 75 mL/min where solvent A was 0.1 % TFA in H 2 0 and solvent B was 0.1 % TFA in 90 % acetonitrile. Yield: peptides 59-64 %, peptide-chelators 68-76 %.
  • Mass spectrum analysis MH+ : peptide (2) : 519, peptide (3) : 666, bio-pep-DTPA (1) : 912, bio-pep-DTPA (2) : 1059, bio- pep-DTPA 13): 1206.
  • the structure of biotin-D-Lys-DTPA is shown below.
  • InCl 3 or YC1 3 200 ⁇ Ci , in 0.05 M HC1 was diluted with 3 volumes of 0.5 M sodium acetate, pH 6.
  • the chelator (8 X 10 "5 M) in 15 ⁇ L of 0.5 M sodium acetate, pH 6 was added and incubated at room temperature for 1 hour.
  • Approximately 0.2 ⁇ Ci of the sample was applied to ITLC (Gelman sciences) pre-spotted with 5 ⁇ L 1 % HSA and developed in 5:2:1 H 2 0 : ethanol : ammonium hydroxide solvent system to determine the extent of labeling.
  • ITLC Gelman sciences
  • ITLC Garman sciences
  • 5 ⁇ L 1 % HSA pre-spotted with 5 ⁇ L 1 % HSA and developed in 5:2:1 H 2 0 : ethanol : ammonium hydroxide solvent system to determine the extent of labeling.
  • the formed chelate moved with the solvent front.
  • Ability to bind to streptavidin was demonstrated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une méthode améliorée permettant de détecter et/ou de traiter des lésions chez un patient. Cette méthode fait appel à une approche de préciblage, et permet d'accroître considérablement la quantité totale de radionucléide délivrée à une cellule, à un tissu ou à un agent pathogène. Le conjugué chélaté peut être purifié par chromatographie après la formation du chélate. Il peut contenir des chélates multiples, ou bien un agent de liaison ou un agent d'addition modifiant le passage dans le sang, ou les deux, ou une combinaison de ces éléments. Ces conjugués chélatés améliorés peuvent être utilisés comme agents de détection ou comme agents thérapeutiques pour détecter ou traiter la cellule, le tissu ou l'agent pathogène ciblé.
PCT/US1997/013285 1996-07-31 1997-07-31 Amelioration de la detection et du traitement de lesions par des conjugues chelates de la biotine WO1998004293A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40474/97A AU4047497A (en) 1996-07-31 1997-07-31 Improved detection and therapy of lesions with biotin-chelate conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68878196A 1996-07-31 1996-07-31
US08/688,781 1996-07-31

Publications (1)

Publication Number Publication Date
WO1998004293A1 true WO1998004293A1 (fr) 1998-02-05

Family

ID=24765740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013285 WO1998004293A1 (fr) 1996-07-31 1997-07-31 Amelioration de la detection et du traitement de lesions par des conjugues chelates de la biotine

Country Status (2)

Country Link
AU (1) AU4047497A (fr)
WO (1) WO1998004293A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030745A3 (fr) * 1997-12-15 2000-01-13 Immunomedics Inc Derives de dota-biotine
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6264917B1 (en) 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
WO2003059397A3 (fr) * 2001-12-26 2003-08-28 Immunomedics Inc Marquage d'agents de ciblage au gallium-68 et au gallium-67

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
US5283342A (en) * 1992-06-09 1994-02-01 Neorx Corporation Biotinylated small molecules
US5326778A (en) * 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
US5326778A (en) * 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
US5283342A (en) * 1992-06-09 1994-02-01 Neorx Corporation Biotinylated small molecules
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6264917B1 (en) 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6680047B2 (en) 1996-10-28 2004-01-20 Amersham Health As Diagnostic/therapeutic agents
WO1999030745A3 (fr) * 1997-12-15 2000-01-13 Immunomedics Inc Derives de dota-biotine
WO2003059397A3 (fr) * 2001-12-26 2003-08-28 Immunomedics Inc Marquage d'agents de ciblage au gallium-68 et au gallium-67
US7011816B2 (en) 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
AU2002356315B2 (en) * 2001-12-26 2008-09-04 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
EP2311500A1 (fr) * 2001-12-26 2011-04-20 Immunomedics, Inc. Marquage d'agents de ciblage avec gallium-68 et gallium-97

Also Published As

Publication number Publication date
AU4047497A (en) 1998-02-20

Similar Documents

Publication Publication Date Title
US6120768A (en) Dota-biotin derivatives
US5958408A (en) Delivery of diagnostic and therapeutic agents to a target site
AU683893B2 (en) Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
JP6821558B2 (ja) 腫瘍細胞を標的にするための代謝産物およびｅｐｒ剤の放射性医薬品コンジュゲート
US5283342A (en) Biotinylated small molecules
CN104334178B (zh) 功能化碳纳米管在肿瘤上的靶向自组装
EP0251494A2 (fr) Composé thérapeutique ou radiodiagnostique
US5607659A (en) Directed biodistribution of radiolabelled biotin using carbohydrate polymers
JPH08509226A (ja) ビオチンやアビジンのポリマー複合体による病変の検出および治療法の改善
CA2178476A1 (fr) Procedes et composes de preciblage
AU3737293A (en) Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
US5911969A (en) Pretargeting protocols for enhanced localization of active agents to target sites
CA2261791A1 (fr) Therapie par capture de neutrons de bore dans laquelle des procedes de pre-ciblage sont utilises
US5746996A (en) Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
IE58425B1 (en) Improved Method of Conjugating Metallothionein to Biologically Active molecules
WO1998004293A1 (fr) Amelioration de la detection et du traitement de lesions par des conjugues chelates de la biotine
Rosebrough Plasma stability and pharmacokinetics of radiolabeled deferoxamine-biotin derivatives.
CA2066031C (fr) Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus
US5914312A (en) Pretargeting methods and compounds
EP0831936B1 (fr) Thiolation de peptides aux fins d'une radiodetection et d'une radiotherapie utilisant des radionuclides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998509083

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase